Angiogenesis In Lymphoma

In an insightful article from 1975, Wolf et al98 described angiogenesis in a cutaneous lymphoma (classified as malignant lymphoma, undifferentiated, non-Burkitt type). They showed that lymphoma fragments stimulated angiogenesis in a hamster cheek pouch model, even when separated by a Millipore membrane.98 This observation led the authors to conclude that a diffusable tumour angiogenic factor may play a vital role in tumour survival and portends a therapeutic potential.98 Experiments using a...

Tcell Prolymphocytic Leukemia Tpll And Tcell Chronic Lymphocytic Leukemia Tcll

Most of the T cell non-Hodgkin lymphomas are relatively rare compared to their B cell counterparts in the Western world, and for this reason, have been less exhaustively studied. Among these uncommon disorders are the entities referred to variously as T-PLL and T-CLL. T-PLL is a rare peripheral T-cell leukemia lymphoma with the following characteristics an absolute lymphocytosis typically with concomitant hepatosplenomegaly, anemia, and thrombocytopenia. The incidence of lymphadenopathy and...

Red Blood Cell Morphology

Abnormalities of red blood cells account for a high percentage of manual blood smear reviews in the clinical hematology laboratory,12 but properly interpreting red cell abnormalities is a deceptively difficult task. Many clinical-morphologic correlates are well-established through decades of accumulated anecdotal experience and in vitro analysis15 and are likely appropriate for clinical practice, but there are actually very few objective or scientific data indicating the sensitivity,...

E21g3

Dystrophin rel prot 2 3UTR of unk prot Uncharacterized Prot kinase C gamma 5-Hydroxytrypta 2B Rec H731 Transducin-line enhancement Uncharacterized Prot kinace C beta 1 Oviductal glycoprot Zinc fing prot C2H2-150 The identification of the predictor genes was based on the analysis of lymphoma cases treated during the past decade, largely prior to the advent of Rituximab chemotherapy. It is unknown whether the same gene subsets will be predictive of response to chemotherapy and survival in...

Classifications of Hodgkins disease

In contrast to non-Hodgkin's lymphomas (NHL), which have undergone many changes in classification, the organizational scheme for Hodgkin's disease has remained remarkably stable for almost 40 years. The first useful classification of Hodgkin's disease was published in 1947 by Jackson and Parker in their book Hodgkin's Disease and Allied Disorders.13 HL was divided into three histologic types paragranuloma, granuloma, and sarcoma (Table 11-1). However, this division was not helpful in predicting...

References

Multiple myeloma evolving genetic events and host interactions. Nat Rev Cancer 2002 2 175-187. 2. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002 1000 1417-1424. 3. Zandecki M, Lai JL, Genevieve F, Bernardi F, Volle-Remy H, Blanchet O, Francois M Cosson A, Bauters F, Facon T. Several cytogenetics subclones may be identified...

Marginal Zone Lymphoma

Marginal zone lymphoma (MZL) represents a subgroup of NHL comprised of low-grade B cell lymphomas occurring in nodal (monocytoid B-cell lymphoma), splenic (splenic marginal zone lymphoma) and extra nodal (low grade lymphomas of mucosa associated lymphoid tissue, MALT) locations.24 Although most commonly a disease of adults,161 recent reports document its occurrence in younger individuals.162 It is an indolent lymphoma with a tendency to remain localized for a prolonged period of time.163,164...

Nodular Lymphocyte Predominant Hodgkin Lymphoma

In the Lukes Butler classification, NLP HL was divided into two morphologic subtypes nodular and diffuse.14,15 In the Rye scheme, it was simply called NLP HL. In the REAL WHO classification, NLP HL is defined as having at least a partially nodular growth pattern, although diffuse areas may be present in a minority of cases.1,19 Table 11-1 Although there is still controversy about whether a purely diffuse LP HL exists, this entity is not recognized as a distinct category in the WHO scheme. The...

Acute Lymphoblastic Leukemia

Most published series of patients with ALL indicate that more than 85 have an abnormal clone by conventional cytogenetic studies. At least 36 chromosome anomalies are common in ALL. The most common karyotype among children with ALL is hyperdiploidy. This karyotype is associated with a good prognosis in the absence of any structural anomalies and when associated with trisomies of chromosomes 4, 10 and 17.90 The most common chromosome translocations in pediatric ALL include t 9 22 q34 q11.2 , t...

Angiogenesis In Myelodysplastic Syndrome Mds And Acute Myeloid Leukemia

Numerous groups have documented increased vascularity in bone marrow biopsies of patients with AML22-29 and MDS,23, 29-31 as compared to normal control bone marrow biopsies. In our study26 we specifically looked at angiogenesis in acute promyelocytic leukemia APL , which is a subtype of AML. We showed that bone marrow angiogenesis is increased in APL, and is decreased after treatment with all-trans retinoic acid. A similar decrease in angiogenesis, after therapy, has been seen in other subtypes...

Acute Myeloid Leukemia

Four cytogenetic risk categories of AML are widely applied in clinical practice favorable, intermediate, unfavorable, and unknown.78,79 Consequently, it is important to perform appropriate cytogenetic and FISH studies to establish the correct cytogenetic risk category to decide appropriate treatment. The favorable cytogenetic risk category anomalies include t 15 17 q22 q21 and variants with or without other chromosome anomalies, with or without other chromosome anomalies and t 8 21 q22 q22...

Future Developments 31 Extended Differential Counts

Once the potential of current technologies is realized, there are several exciting developments that will be available for clinical use in the near future. Among the most imminent of these functions is the automated extended differential count EDC . Currently, automated leukocyte differential counts are highly accurate and precise, but they are limited by the inability of typical analyzers to precisely quantify abnormal cell types and certain granulocyte forms metamyelocytes, myelocytes,...

Ancillary Studies For Diagnosis And Subclassification Of Ml

The WHO classification for ML 30 emphasizes the importance of clinical features combined with morphological, immunophenotypic and genotypic characteristics for diagnosis and categorization of ML and postulates a cell of origin for each neoplasm, which in many cases reflects the stage of differentiation of the malignant cell.30 Small - Chronic Round - Large cell leukemia small chromatin immunoblastic lymphocytic lymphoma with Large - Large cell Convoluted - Follicular Carcinoma chromatin -...

Autoverification in the Clinical Hematology Laboratory

As analytical methods in automated laboratories become faster and more efficient, the rate-determining step for the release of information to the patient record is no longer the generation of data, but our ability to process and manage data. Medical technologists are responsible for numerous complex and integrated tasks in the clinical laboratory that require subjective or interpretive skill. In addition to these necessarily manual tasks, however, many of the decisions made by medical...

Bone Marrow Transplantation

Various FISH strategies are available to monitor patients after bone marrow transplantation. FISH probes for the X and Y chromosome can be used for opposite-sex bone marrow transplantation to detect levels gt 0.3 XY cells in females and gt 0.6 XX cells in males33 This method defines the ratio of host versus donor cells, but does not directly establish the percentage of neoplastic cells. Alternatively, an appropriate FISH assay can be used to establish the percentage of neoplastic cells. The...

Info

C.G. , Cytogenetics Laboratory, Mayo Clinic, Rochester Minnesota Gerald M. Davis, M.P.H., M.T. A.S.C.P. , Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan Gordon W. Dewald, Ph.D., Cytogenetics Laboratory, Mayo Clinic, Rochester, Minnesota William G. Finn, M.D., Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan John L. Frater, M.D., Department of Clinical Pathology, Division of Pathology,...